There were 585 press releases posted in the last 24 hours and 150,666 in the last 365 days.

HealthMyne Enters Joint Development Agreement with Mayo Clinic


Mayo Clinic Evaluates Therapy Response Assessment Module of HealthMyne QIDS Platform

MADISON, WI, UNITED STATES, September 7, 2018 / -- HealthMyne has signed a joint development agreement with Mayo Clinic to evaluate the Quantitative Imaging Decision Support (QIDS)® platform in their Scottsdale, AZ facility for Therapy Response Assessments, which allows for a standardized method of determining the effectiveness of various treatment protocols used in cancer care. In current practice, due to significant inefficiencies in the process, these assessments are generally limited to patients involved in clinical trials.

HealthMyne’s QIDS platform enables better patient management decisions for hospital providers worldwide by connecting the Point-of-Read (Radiology) with the Point-of-Care starting with Oncology and expanding to other specialties over time. The QIDS platform drives collaboration by providing the multidisciplinary care team with intuitive, workflow-integrated software that leverages imaging and clinical data to enhance the quality and cost of care. The Clinical Decision Support (CDS) modules in the platform--Cancer Screening, Tumor Conferences, Therapy Response, Incidental Findings, Thoracic, others--significantly automate and streamline inefficient and cost-intensive clinical processes to allow busy clinicians to focus their energies on precise patient management.

Dr. Linda Peitzman, CMIO for HealthMyne, states, “The QIDS platform provides an easy way to consistently measure Therapy Response for all cancer patients enabling clinicians to understand much earlier if a patient is responding to treatment and make appropriate adjustments in their protocols. This can result in better care and lower costs. Extracting additional volumetric and radiomic data during the clinical read can also significantly advance biomarker discovery and move us closer to personalized medicine.”

HealthMyne’s proprietary algorithms automate the extraction of quantitative imaging metrics at the Point-of-Read, minimizing inter- and intra-reader variability. The Therapy Response Module automates response scoring and the tracking of cancerous lesions across studies and time-points, greatly reducing the manual work effort. Protocols can be based on standards such as RECIST or iRECIST, but the module is extremely flexible allowing for custom parameters. The entire module is managed in a web-based environment making it easy to setup and use.

About HealthMyne
HealthMyne, Inc. (HM; Madison, WI) is focused on delivering Quantitative Imaging Decision Support (QIDS)® for Radiology and Oncology to U.S.-based multi-hospital systems with expansion to non-U.S. markets and other clinical specialties over time. The company’s FDA-cleared software platform's novel Rapid Precise Metrics (RPM)™ algorithms deliver Point-of-Read image-derived curated metrics integrated with other clinical systems data (e.g. PACS, EMR, RT) into multiple Point-of-Care workflow modules to ensure timely clinical decision support (CDS) and precise patient management. The QIDS platform provides actionable, patient-centric reports and an integrated clinical and imaging dashboard (PatientCare Timeline®) to optimize collaboration among the multidisciplinary care team. Additionally, the platform’s discoverable database supports data mining and AI-based application development for Precision Medicine/Big Data initiatives and for innovative clinical, translational, and commercial research by both medical centers and pharmaceutical/biotech companies.

Neal Miller
email us here

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.